Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01175395 · ClinicalTrials.gov registry record · Phase 1
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
A Phase 1 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01175395 is a Phase 1 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 10 participants.
The verdict
NCT01175395, a Phase 1 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the safety \& tolerability of an investigational drug 20089 TA (6.9 mg or 13.8 mg) when used adjunctively with Lucentis 0.5 mg in subjects with sub-foveal neovascular AMD.
Interventions
- DRUG IBI-20089/Lucentis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01175395
The ClinicalTrials.gov registry entry for NCT01175395 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IBI-20089/Lucentis is the first listed.
NCT01175395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01175395 about?
NCT01175395 is a clinical study titled "20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)". The primary purpose of this study is to assess the safety \& tolerability of an investigational drug 20089 TA (6.9 mg or 13.8 mg) when used adjunctively with Lucentis 0.5 mg in subjects with sub-foveal neovascular AMD.
What is the current status of trial NCT01175395?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2010-09. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01175395?
The interventions under investigation include: IBI-20089/Lucentis (DRUG).
Who is sponsoring clinical trial NCT01175395?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.